 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Clene Inc. (NASDAQ:CLNN  Get Free Report) has received a consensus rating of Buy from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. Six...

Clene Inc. (NASDAQ:CLNN) Receives Average Rating of "Buy" from Brokerages

Clene Inc. (NASDAQ:CLNN  Free Report)  Equities researchers at HC Wainwright reduced their FY2023 earnings per share estimates for shares of Clene in a note issued to investors on...

HC Wainwright Comments on Clene Inc.'s FY2023 Earnings (NASDAQ:CLNN)

Clene Inc. (NASDAQ:CLNN  Get Free Report)s share price was down 3.6% during trading on Thursday . The stock traded as low as $0.39 and last traded at $0.40. Approximately 147,555 shares...

Clene (NASDAQ:CLNN)  Shares Down 3.6%

Reported statistically significant improved survival benefit of 19.3 months and significantly delayed clinical worsening in patients treated with CNM-Au8 in the RESCUE ALS open-label extension...

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Clene awarded $45.1M four-year grant from NINDS for CNM-Au8

Funding to Support Research and Expanded Access of Investigational Drug in ALSSALT LAKE CITY, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), through its wholly owned subsidiary Clene...

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8  Study in ALS

Prolonged life with 49% decreased risk of death for participants in the HEALEY ALS Platform Trial treated with CNM-Au8 30mg compared to PRO-ACT matched placebo over long-term follow-up...

Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls

SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, Clene ) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage...

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference

Clene Inc. (NASDAQ:CLNN  Get Free Report) saw a large decline in short interest during the month of August. As of August 31st, there was short interest totalling 410,400 shares, a decline of...

Short Interest in Clene Inc. (NASDAQ:CLNN) Declines By 28.4%

SALT LAKE CITY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, Clene) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to ...

Clene to Present at Upcoming September Conferences

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded on August 12, 2020 and is headquartered in Salt Lake City, UT.

Watchers	2,754
52-Wk Low	$0.3576
52-Wk High	$1.99

Market Cap	$31.36M
Volume (M)	326,498.00
52-Wk High	$1.99
52-Wk Low	$0.3576

Current Price	$0.40
Prev Close	$0.40
Open	$0.42
Dividend Yield	0.00%
50-Day Moving Average	$0.4584
Beta	0.76
Avg. Volume	293,997.33
PE Ratio	-0.83

52-Week High	$1.99
52-Week Low	$0.3576
Market Capitalization	$31.36M
EPS	-$0.4799
Price to Book	2.40
Revenue Per Employee	$8,348.84
Enterprise Value/EBITDA	-1.33

CLNN Clene Inc

About

Feed

News

Sentiment

Earnings

Fundamentals